Boston reinforces clinical evidence to support Taxus platform
This article was originally published in Clinica
Executive Summary
With the drug-eluting stent (DES) market poised to become increasingly crowded, Boston Scientific has released a new round of clinical data that it hopes will help it retain its number one position in the industry.